Cosmetic Peptides

Matrixyl 3000

For Research Use Only. Not for Human or Veterinary Use.

Overview

Matrixyl 3000 is not a single molecule but a two-peptide system: Palmitoyl Tripeptide-1 (Pal-GHK) paired with Palmitoyl Tetrapeptide-7 (Pal-GQPR). The idea studied in the literature is complementary action — one peptide is a collagen-oriented matrikine, the other is investigated for calming the inflammatory signalling that degrades matrix — so together they are researched as a broader approach to dermal-matrix support than either alone.

Chemical Profile

The blend contains two independently synthesized palmitoylated peptides, typically combined at about a 6 : 4 ratio (Tripeptide-1 : Tetrapeptide-7).

Component 1 — Palmitoyl Tripeptide-1Value
CAS number147732-56-7
INCI namePalmitoyl Tripeptide-1
Amino-acid sequencePal-Gly-His-Lys-OH (Pal-GHK)
Molecular formulaC₃₀H₅₃N₇O₆
Molecular weight673.83 g/mol
Component 2 — Palmitoyl Tetrapeptide-7Value
CAS number221227-05-0
INCI namePalmitoyl Tetrapeptide-7
Amino-acid sequencePal-Gly-Gln-Pro-Arg-OH (Pal-GQPR)
Molecular formulaC₃₀H₅₂N₈O₇
Molecular weight520.68 g/mol
Matrixyl 3000 at a glance
Class
Dual palmitoylated matrikine system
Component 1
Pal-Tripeptide-1 — collagen-oriented
Component 2
Pal-Tetrapeptide-7 — anti-inflammatory research
Typical blend ratio
≈ 6 : 4 (T1 : T7)
Typical route
Topical
Reference trade name
Matrixyl™ 3000 (Sederma / Ashland)

Mechanism of Action

The two peptides are studied for different but reinforcing roles. Palmitoyl Tripeptide-1 carries the GHK sequence and is investigated as a matrikine that signals collagen synthesis; Palmitoyl Tetrapeptide-7 is modelled on an immunoglobulin fragment and is studied for damping pro-inflammatory cytokines that would otherwise drive matrix breakdown.

Palmitoyl Tripeptide-1 (collagen)Research description
Primary targetFibroblast TGF-β signalling
MechanismMatrikine cue for procollagen synthesis
Collagen typesAssociated with collagen I, III and IV
Wider ECMFibronectin, elastin and laminin in models
Palmitoyl Tetrapeptide-7 (anti-inflammatory)Research description
Primary targetPro-inflammatory cytokine signalling (e.g. IL-6, IL-1β)
MechanismStudied for downregulating cytokine output from stimulated fibroblasts
Origin mimicModelled on an immunoglobulin-G heavy-chain fragment
Protective roleExplored for limiting cytokine-driven collagen degradation

The research rationale for the blend is synergy: one peptide is investigated for building matrix while the other is investigated for protecting it, so the combination is studied as more complete than a single matrikine.

Pharmacology

ParameterPalmitoyl Tripeptide-1Palmitoyl Tetrapeptide-7
logP≈ 4.0 (lipophilic)≈ 3.8 (lipophilic)
Topical bioavailability~5–10%~5–10%
StabilityHigh (palmitoyl protection)High (palmitoyl protection)
MetabolismProteolytic breakdownProteolytic breakdown
RouteTopicalTopical

Research Evidence

Matrixyl 3000 is studied both as a two-peptide system and by its individual components, in cell-based (preclinical) and human (clinical) research.

Combined ECM research

Studied where both collagen synthesis and matrix protection are the endpoints, rather than collagen alone.

Anti-inflammatory tone

The Tetrapeptide-7 component is used to explore cytokine modulation in fibroblast models.

Formulation development

Used in clinical-style anti-aging formulation research as a ready dual-peptide system.

Matrikine comparison

A frequent comparator against single matrikines such as Matrixyl.

Preclinical research — representative models and what they investigate:

ModelResearch focusReference
Human dermal fibroblastsCollagen synthesis (Tripeptide-1 component)Katayama K, et al. (1993)
Stimulated fibroblastsPro-inflammatory cytokine (IL-6) modulation (Tetrapeptide-7)Schagen SK (2017, review)
Aged human fibroblastsECM-related gene-expression profileGorouhi F, Maibach HI (2009)
Human skin (ex vivo)Penetration of both peptide componentsLupo MP, Cole AL (2007)

Clinical research — the types of human study in which the blend is examined:

Study typeEndpoints studiedReference
Topical anti-aging creamWrinkle appearance, firmness and elasticityGorouhi F, Maibach HI (2009)
Formulation efficacy studiesOverall wrinkle severity and skin textureSchagen SK (2017)

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Collagen stimulation plus anti-inflammatory (IL-6) modulationaged human fibroblastscosmetic-peptide literature
Comprehensive ECM / anti-aging endpointsformulation studiesGorouhi F, Maibach HI (2009)

For laboratory research and cosmetic formulation study only. Descriptions refer to published research contexts and are not product or health claims.

Formulation & Dosing Reference

ParameterValue
Typical topical concentration1–8% (w/w) of the blend
Common working range3–5%
Component ratio≈ 6 : 4 (Tripeptide-1 : Tetrapeptide-7)
Solubility in waterPoor (< 1 mg/mL) — co-solvent or emulsion needed
Solubility in DMSO≥ 50 mg/mL
Recommended formulation pH5.0–7.0
Storage (powder)2–8°C, sealed, dry, protected from light

Safety Profile

AssessmentReported result
Acute oral toxicity (rat)LD50 > 2000 mg/kg
Dermal irritation (rabbit)Non-irritant at 8%
Ocular irritation (rabbit)Mild, transient
Skin sensitization (GPMT)Non-sensitizing
Mutagenicity (Ames)Negative
INCI statusBoth components approved cosmetic ingredients

Physicochemical Properties

PropertyPal-Tripeptide-1Pal-Tetrapeptide-7
AppearanceWhite to off-white powderWhite to off-white powder
Molecular weight673.8 Da520.7 Da
logP≈ 4.0≈ 3.8
Solubility in water< 1 mg/mL< 1 mg/mL
Solubility in DMSO≥ 50 mg/mL≥ 50 mg/mL

Synthesis & Manufacturing

The two peptides are synthesized separately by solid-phase peptide synthesis, each palmitoylated at the N-terminus, purified, and then combined at the target ratio.

StepDetail (both components)
StrategySolid-phase peptide synthesis, Fmoc/tBu chemistry
ResinWang resin (C-terminal acid)
CouplingHATU / HBTU with DIPEA
PalmitoylationPalmitic acid coupled to the N-terminus after final Fmoc removal
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5)
PurificationPreparative RP-HPLC (C18, high-organic gradient)
BlendingPurified peptides combined ≈ 6 : 4 by weight (dry blend or co-lyophilization)

Analytical Methods

Because Matrixyl 3000 is a blend, quality control characterises each peptide and confirms the ratio of the two.

MethodPurposeTypical result
RP-HPLC (C18, UV 214 nm)Purity (combined)≥ 95%
RP-HPLCComponent ratioTwo resolved peaks ≈ 6 : 4 (T1 : T7)
ESI-MS (positive mode)Identity / massMasses consistent with both palmitoyl peptides
LC-MS/MSPalmitoylation siteN-terminal palmitoylation confirmed (each component)
Karl FischerWater content< 5%

Representative RP-HPLC method (high-organic gradient for the palmitoylated peptides):

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: 60–90% B over ~20 min · Flow rate: 1.0 mL/min
  • Detection: UV 214 nm — the two components elute as separate, well-resolved peaks

Stability Data

Both components carry a protective palmitoyl group, so the blend behaves much like Matrixyl — stable as a powder and in emulsions, with pH and emulsification as the main variables.

ConditionDurationResult
Lyophilized blend, 2–8°C, dark≥ 24 monthsNo significant degradation
Lyophilized blend, 25°C, dark≥ 12 monthsMinimal degradation
Formulated O/W emulsion, 25°C12+ monthsBoth peptides largely retained
Light exposure (ICH Q1B)StandardLight-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable
  • The palmitoyl groups protect both peptides against exopeptidases, giving good powder and emulsion stability.
  • An emulsion or co-solvent is needed for aqueous systems; optimal pH is 5.0–7.0.

Selected References

Representative peer-reviewed literature relevant to the Matrixyl 3000 peptides. Listed for research reference.

  • Katayama K, et al. A pentapeptide from type I procollagen promotes extracellular matrix production. Journal of Biological Chemistry, 1993.
  • Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 2009.
  • Lupo MP, Cole AL. Cosmeceutical peptides. Dermatologic Therapy, 2007.
  • Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics, 2017.

Quality & Supply

  • Each component HPLC-characterized with a Certificate of Analysis
  • Identity confirmed by LC-MS; blend ratio verifiable
  • Research samples through to bulk, with worldwide delivery
  • Custom ratios and packaging on request

Need Matrixyl 3000 — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote